Atomoxetine treatment of children and adolescents with ADHD: Clinical questions and answers;Atomoxetinbehandlung von kindern und jugendlichen mit ADHS: Klinische fragen und antworten

Monatsschrift fur Kinderheilkunde

Volumn 154, Issue 9, 2006, Pages 894-902

  Sevecke, K ^a   Dittmann, R ^b,c   Lehmkuhl, G ^a   Dopfner M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

ADHD; Adverse events; Atomoxetine; Efficacy; Pharmacotherapy

Indexed keywords

AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO;

ADOLESCENCE; ATTENTION DEFICIT DISORDER; CHILDHOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DECREASED APPETITE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; RHINITIS; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED STATES;

EID: 33750286659     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-005-1153-y     Document Type: Review

References (47)

1. Adam C, Döpfner M, Lehmkuhl G (2002) Der Verlauf von Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (ADHS) im Jugend- und Erwachsenenalter. Kindheit Entwicklung 11:73-81
2. Adler L, Spencer T, Michelson D et al. (2003) Long-term treatment effects of atomoxetine in adults with attention-deficit/hyperactivity disorder (ADHD). Poster, ECNP, Prag, Abstractband 458
3. Adler L, Spencer T, Reimherr F et al. (2003) Efficacy and safety of atomoxetine in long-term open label treatment of adults with ADHD. Poster, American Pediatric Academy (APA), San Francisco, Abstractband 241
4. Allen AJ, Milton DR, Michelson D et al. (2003) Efficacy of atomoxetine treatment for adolescents with attention-deficit/hyperactivity disorder. Poster, American Pediatric Academy (APA), San Francisco
5. Banaschewski T, Roessner V, Dittmann RW et al. (2004) Non-stimulant medications in the treatment of ADHD. Eur J Child Adolesc Psychiatry 13(Suppl 1):102-116
6. Belle DJ, Ernest CS, Sauer JM et al. (2002) Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacogenetics. J Clin Pharmacol 42:1219-1227
7. Biedermann J, Heiligenstein JH, Faries DE et al. (2002) Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/ hyperactivity disorder. Pediatrics 6:1-7
8. Brown WJ, Wernicke J, Allen AJ et al. (2002) Efficacy of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Poster, American Pediatric Academy (APA), Philadelphia
9. Bymaster FP, Katner JS, Nelson DL et al. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
10. Döpfner M, Banaschewski T, Schmidt J et al. (2003) Langzeitwirksames Methylphenidat bei Kindern mit Aufmerksamkeitsdefizit- Hyperaktivitätsstörungen - Eine multizentrische Studie. Nervenheilkunde 22:85-92
11. Döpfner M, Breuer D, Schürmann S et al. (2004) Effectiveness of an adaptive multimodal treatment in children with attention deficit hyperactivity disorder-global outcome. Eur Child Adolesc Psychiatry 13(Suppl 1):I/117-I/129
12. Döpfner M, Frölich J, Lehmkuhl G (2000) Hyperkinetische Störungen. Leitfaden Kinder- und Jugendpsychotherapie. Hogrefe, Göttingen
13. Döpfner M, Gerber WD, Banaschewski T et al. (2004) Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 13(Suppl 1):I/93-I/101
14. Döpfner M, Lehmkuhl G (2002) Evidenzbasierte Therapie von Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). Prax Kinderpsychol Kinderpsychiatr 51:419-440
15. Garland EJ (1998) Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol 12:385-395
16. Kelsey D, Sumner C, Sutton V et al. (2003) Once-daily atomoxetine in childhood ADHD: continuous symptom relief ADHD. Eur J Child Adolesc Psychiatry 12(Suppl 2):143
17. Kelsey DK, Sumner CR, Casat CD et al. (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114:1-8
18. Kelsey D, Malcom S, Bakken R et al. (2004) Effect of atomoxetine in treating pediatric ADHD in a natural setting. Poster, American Academy of Child & Adolescent Psychiatry (AACAP), Washington, Nr. A21
19. Kratochvil C, Newcorn J, Gao H et al. (2003) Atomoxetine for comorbid ADHD and affective symptoms. Poster, American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband 160
20. Kratochvil C, Heiligenstein JH, Dittmann R et al. (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatr 41:776-784
21. Kratochvil CJ, Milton D, Vaughan B et al. (2003) Atomoxetine in the treatment of young children with ADHD. Poster, American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband 147
22. Kratochvil CJ, Vaughan BS, Harrington MJ et al. (2003) Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 4:1165-1174
23. Krachtovil CJ, Wilens TE, Greenhill LL et al. (2004) Effects of long-term atomoxetine treatment for young children with ADHD. Poster, International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Abstractband 325
24. Mc Cracken JT, Sallee FR, Leonard HL et al. (2003) Improvement of ADHD by atomoxetine in children with tic disorders. Poster, American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband 117
25. Michelson D, Adler L, Spencer T et al. (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. World J Biol Psychiatry 53:112-120
26. Michelson D, Allen AJ, Busner J et al. (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
27. Michelson D, Buitelaar J, Danckaerts M et al. (2003) Results from a long-term trial of atomoxetine in the prevention of relapse in ADHD. Eur J Child Adolesc Psychiatry 12:142
28. Michelson D, Faries D, Wernicke J et al. (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 5:1-9
29. Newcorn J, Michelson D, Spencer T (2003) Atomoxetine treatment in children/adolescent ADHD with comorbid ODD. Eur J Child Adolesc Psychiatry 12(Suppl 2):142-143
30. Perwien AR, Faries D, Kratochvil C (2003) Long-term effects of atomoxetine on health-related quality of life. Poster, American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband 168
31. Sangal RB, Owens J, Allen AJ et al. (2004) Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Poster, International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP), Berlin, Abstractband 189
32. Schachter HM, Pham B, King J et al. (2001) How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475-1488
33. Sevecke K, Battel S, Dittmann RW et al. (2005) Die Wirksamkeit von Atomoxetin bei Kindern, Jugendlichen und Erwachsenen mit ADHS - eine systematische Übersicht. Nervenarzt (im Druck)
34. Sevecke K, Döpfner M, Lehmkuhl G (2004) Die Wirksamkeit von Stimulanzien-Retardpräparaten bei Kindern und Jugendlichen mit ADHD - eine systematische Übersicht. Z Kinder Jugendpsychiatr 32:3-12
35. Spencer T, Biederman J, Wilens T et al. (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432
36. Spencer T, Biedermann J, Heiligenstein J et al. (2001) An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 3:251-265
37. Spencer T, Heiligenstein MD, Biedermann J et al. (2002) Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 12:1140-1147
38. Spencer TJ, Ruff DR, Feldman PD et al. (2003) Long-term effects of atomoxetine on growth in children and adolescents with ADHD. Poster, American Academy of Child & Adolescent Psychiatry (AACAP), Miami, Abstractband 170
39. Spencer TJ, Zhang S, Ruff DD et al. (2004) Developmental outcomes of long-term atomoxetine treatment in juveniles with ADHD. Poster, International Association of Child and Adolescents Psychiatry and Allied Professions (IACAPAP), Berlin, Abstractband 324
40. Sutton VK, Milton DR, Ruff DD et al. (2004) Atomoxetine's efficacy over time in children and adolescents with attention-deficit/hyperactivity disorder. Poster, International Association of Child and Adolescents Psychiatry and Allied Professions (IACAPAP), Berlin, Abstractband 331
41. Taylor E, Döpfner M, Sergeant J et al. (2004) Clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):I/7-I/30
42. Weiss M, Tannock R, Krachtovil C et al. (2003) Placebo-controlled study of once-daily atomoxetine in the school setting. Eur J Child Adolesc Psychiatry 12:143
43. Wernicke JF, Faries D, Girod D et al. (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729-740
44. Wernicke JF, Kratochvil ChJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63:50-55
45. Wigal SB, McGough JJ, McCracken JT et al. (2004) Analog classroom study of amphetamine extended release and atomoxetine in youth with ADHD. Poster, American Psychiatric Association (APA), New York
46. Wilens TE, Newcorn JH, Krachtovil CH et al. (2004) Do children and adolescents with ADHD respond differently to atomoxetine? Poster, American Psychiatric Association (APA), New York
47. Wilens T, Newcorn J, Krachtovil CH et al. (2004) Longer-term treatment with atomoxetine in adolescents with ADHD. Poster, American Psychiatric Association (APA), New York